Project Grant R21CA297395
Award Date
12/9/24
Completion Date
11/30/26
Dollars Obligated
$206K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Birmingham, AL 35294, USA
Similar Awards
The National Cancer Institute awarded a $585,228 Project Grant (CFDA 93.395 - Cancer Treatment Research) to the University of Alabama at Birmingham (UAB) to develop and evaluate a novel antibody-drug conjugate (ADC) delivery platform. The grant will support research to confirm the effectiveness of UAB's patented polymer-based in vivo delivery system, which enables enhanced tumor-specific targeting, improved drug-antibody ratios, and greater anti-cancer efficacy compared to existing ADCs. Key...
This $627,573 federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to optimize radioligand therapy dosimetry and kidney biomarkers for alpha-emitter radiotherapy in neuroendocrine tumors. The key products and services to be delivered include: Developing a detailed understanding of the role of superoxide dismutation in tubular DNA repair following alpha-emitter radiotherapy Identifying optimal dosing regimens of the [212Pb]Pb-VMT-A-NET...
The National Cancer Institute (NCI) awarded a $644,034 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to develop a nanoparticle-based drug delivery platform that uses radiation to control the release of chemotherapy payloads within irradiated tumor tissue. The project aims to expand the therapeutic window of chemoradiation by improving local disease control while mitigating...
The National Cancer Institute (NCI) awarded a $695,205 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to The Trustees of the University of Pennsylvania, doing business as the Clinical Practices of the University of Pennsylvania. The grant, effective June 1, 2025 through May 31, 2030, will support early phase clinical trials of 211At-meta-astatobenzylguanidine (211At-MABG) for the treatment of neuroblastoma in children and advanced neuroendocrine cancers in adults....
This $644,622 Project Grant, awarded by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), aims to enhance the efficacy of radioligand therapy for metastatic castrate-resistant prostate cancer. The key products and services to be delivered include: Developing a novel method for bone marrow dosimetry by coupling macro/micro Monte Carlo modeling with imaging data on lesion and marrow distribution in spongiosa. Building predictive models to forecast absorbed...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the development of a novel dual-targeting ligand called BG-P-TAT (NP855) for the treatment of high-risk neuroblastoma. Nanopharmaceuticals LLC, the awardee, is evaluating the efficacy and safety of this ligand, which combines a plasma membrane integrin αvβ3 antagonist and a norepinephrine transporter (NET) targeting compound. The $792,367 award will fund studies to confirm the in...
This Project Grant award of $662,516 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to evaluate how fractionated radiation affects the tumor microenvironment to influence passive drug delivery. The key research objectives are: Quantify how local radiation reshapes the tumor microenvironment to impact passive drug delivery in mouse and patient-derived cancer models, using in vivo imaging, multiplexed microscopy, and functional perturbations. Test whether...
The National Cancer Institute (NCI) awarded Oncotab, Inc. a $400,000 Project Grant (CFDA 93.395 - Cancer Treatment Research) to develop an optimized targeted radiotherapy for pancreatic ductal adenocarcinoma (PDAC). The goal is to overcome the challenges of delivering effective treatments to PDAC tumors, which have a very low 5-year survival rate of less than 9%. The project will involve a structured design of experiments to evaluate the use of a humanized tumor-associated MUC1 (TMUC1)...
This Project Grant award, funded by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), supports the development and evaluation of an innovative approach to target mesothelioma, a devastating form of cancer. The $696,447 award will enable researchers at the University of Virginia to build on their discovery of a novel tumor-selective antibody that binds to the CD46 epitope, which is highly expressed across all major mesothelioma subtypes. The research aims to...
This $255,730 National Science Foundation project grant supports the development of self-assembling molecular brachytherapy for treatment of metastatic cancer. The goal is to enable radiation therapies for metastatic cancer, which accounts for approximately 90% of cancer deaths in the United States each year. The grantee, Oncurie, LLC, seeks to advance a radiotherapy approach that exploits cancer cells themselves as catalysts for therapeutic delivery. Specifically, the company will develop an...